within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M03B_MuscleRelaxantsCentrallyActingAgents.M03BX07_Tetrazepam;

model Tetrazepam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 9.722222222222224e-07,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.0009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.021666666666666667,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tetrazepam</td></tr><tr><td>ATC code:</td><td>M03BX07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.05</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tetrazepam is a benzodiazepine derivative formerly used as a muscle relaxant for the relief of painful muscle spasms and related conditions. It has anxiolytic properties similar to other benzodiazepines. Tetrazepam has been withdrawn from the market in many countries due to reports of severe cutaneous adverse reactions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M03BX07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tetrazepam;
